JP2023524064A5 - - Google Patents

Info

Publication number
JP2023524064A5
JP2023524064A5 JP2022566323A JP2022566323A JP2023524064A5 JP 2023524064 A5 JP2023524064 A5 JP 2023524064A5 JP 2022566323 A JP2022566323 A JP 2022566323A JP 2022566323 A JP2022566323 A JP 2022566323A JP 2023524064 A5 JP2023524064 A5 JP 2023524064A5
Authority
JP
Japan
Prior art keywords
clofazimine
pharmaceutically acceptable
inhalable
composition according
polymorph
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022566323A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524064A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/030155 external-priority patent/WO2021222740A1/en
Publication of JP2023524064A publication Critical patent/JP2023524064A/ja
Publication of JP2023524064A5 publication Critical patent/JP2023524064A5/ja
Pending legal-status Critical Current

Links

JP2022566323A 2020-05-01 2021-04-30 ウイルス感染を治療又は予防するためのクロファジミン組成物及び方法 Pending JP2023524064A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063018677P 2020-05-01 2020-05-01
US63/018,677 2020-05-01
PCT/US2021/030155 WO2021222740A1 (en) 2020-05-01 2021-04-30 Clofazimine composition and method for the treatment or prophylaxis of viral infections

Publications (2)

Publication Number Publication Date
JP2023524064A JP2023524064A (ja) 2023-06-08
JP2023524064A5 true JP2023524064A5 (enExample) 2024-05-09

Family

ID=78332269

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022566323A Pending JP2023524064A (ja) 2020-05-01 2021-04-30 ウイルス感染を治療又は予防するためのクロファジミン組成物及び方法

Country Status (9)

Country Link
US (1) US20230248722A1 (enExample)
EP (1) EP4142691A4 (enExample)
JP (1) JP2023524064A (enExample)
KR (1) KR20230005937A (enExample)
CN (1) CN115666510A (enExample)
AU (1) AU2021263580A1 (enExample)
BR (1) BR112022022081A2 (enExample)
CA (1) CA3177438A1 (enExample)
WO (1) WO2021222740A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240390366A1 (en) * 2021-11-30 2024-11-28 Mannkind Corporation Formulation and method for topical treatment of mycobacterium ulcerans in buruli ulcers
WO2025091042A1 (en) * 2023-10-27 2025-05-01 Mannkind Corporation Methods for treating non-tuberculous mycobacterial infection

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071127B2 (en) * 2006-10-24 2011-12-06 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
ES2929343T3 (es) 2008-06-13 2022-11-28 Mannkind Corp Inhalador de polvo seco accionado por aspiración para la administración de fármacos
EP2496253B1 (en) * 2009-11-02 2019-01-09 MannKind Corporation Apparatus and method for cryogranulating a pharmaceutical composition
AU2014228415B2 (en) * 2013-03-15 2018-08-09 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
CA2943049A1 (en) * 2014-04-08 2015-10-15 Aradigm Corporation Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria
CA2965258C (en) * 2014-10-24 2023-09-19 Redhill Biopharma Ltd. Therapy for inhibition of single-stranded rna virus replication
US20160220710A1 (en) * 2015-01-30 2016-08-04 The Regents Of The University Of Michigan Compositions and methods for delivering pharmaceutical agents
CN108853106B (zh) * 2017-05-09 2021-02-02 中国食品药品检定研究院 亚胺吩嗪类化合物作为狂犬病病毒抑制剂的用途
US20200297626A1 (en) * 2017-10-02 2020-09-24 Board Of Regents, The University Of Texas System Inhalable composition of clofazimine and methods of use thereof
WO2019110099A1 (en) * 2017-12-06 2019-06-13 Qrumpharma Inc. Inhalable clofazimine formulation
KR102834026B1 (ko) * 2018-08-23 2025-07-14 맨카인드 코포레이션 클로파지민의 조성물, 이들을 포함하는 조합물, 이들의 제조 방법, 이들을 포함하는 용도 및 방법

Similar Documents

Publication Publication Date Title
CN111297838A (zh) 一种抗病毒药物的吸入喷雾剂
JP2008536546A5 (enExample)
JP2014503598A5 (enExample)
CN102186458A (zh) 治疗慢性阻塞性肺病及其它肺疾病的方法
US20160346246A1 (en) Methods for the treatment of lung diseases with mast cell stabilizers
JP2002532520A (ja) 気道病治療および気道用薬剤送達のための化合物および方法
CN102448438A (zh) 抗流行性感冒调配物及方法
JP2008513445A (ja) 吸入による送達で治療効果のある薬剤の許容性の改善方法
JP2023524064A5 (enExample)
JP2013539784A (ja) 嚢胞性線維症の吸入デヌホソルでの治療方法
JP2023524064A (ja) ウイルス感染を治療又は予防するためのクロファジミン組成物及び方法
JP2024531784A (ja) トブラマイシン吸入溶液を含む薬学的組立品及びその使用
US20180110774A1 (en) Compositions and methods for treatment of pulmonary hypertension
CA2701388C (en) Calcium glycerophosphate for treating and preventing respiratory diseases or conditions
TW201016215A (en) Compositions and uses of antiviral active pharmaceutical agents
KR20230035518A (ko) 선천적 면역 반응을 생성하기 위한 퀴닌과 그의 용도
US20220202700A1 (en) Compositions for the treatment of viral pulmonary infections
JPWO2017022814A1 (ja) ネブライザー用組成物
NZ717528B2 (en) Aerosol tyrosine kinase inhibitor compounds and uses thereof
NZ717528A (en) Aerosol tyrosine kinase inhibitor compounds and uses thereof
TW202602487A (zh) 呼吸系統疾病的治療與預防
US20220152157A1 (en) Compositions for the treatment of viral pulmonary infections
HK40083799A (en) Clofazimine composition and method for the treatment or prophylaxis of viral infections
Challoner Aerosol delivery of antibiotics
Abdalaziz et al. Formulation strategy for hydroxychloroquine as inhaler dosage from as a potential for COVID-19 treatment